Switch Planning Steps Build OTCs On Prior Successes
This article was originally published in The Tan Sheet
Firms interested in entering the switch market should look for candidates that build on the success of previous switches. But before they invest in a switch an Rx to OTC status, they should distinguish a consumer understanding of the drug, assess the safety profile and confirm the business opportunity, consultants with NCI Consulting say.
You may also be interested in...
To fully capitalize on potential sales, Rx-to-OTC switch sponsors must plan marketing strategies years before a switch is proposed and continue for years after launch, IRI data shows. Other factors include working with managed care, product differentiation, pricing and consumer satisfaction.
Rx-to-OTC switch sponsors should not wait for FDA to act on NSURE before proposing innovative switch solutions, because reviewers are open to discussing ideas now, an agency official says. Some experts predict the new switch paradigm will not yield concrete regulatory changes, and are promoting other ways to expand OTC access.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.